Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26294337 | 0.98 | CYP1A2 (0.52) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL6343046 | 0.94 | CYP1A2 (0.55) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL850479 | 0.88 | GAA (0.45) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL10291250 | 0.85 | CYP1A2 (0.43) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL196812 | 0.85 | CYP1A2 (0.48) | CYP1A2GAAALDH1A1ALOX15TSHR | |
| SCHEMBL8999653 | 0.84 | GAA (0.49) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL6902942 | 0.83 | CYP1A2 (0.48) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL10291177 | 0.83 | CYP1A2 (0.48) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL8570508 | 0.82 | CYP1A2 (0.73) | CYP1A2GAAALDH1A1ALOX15TDP1 | |
| SCHEMBL50610 | 0.82 | CYP1A2 (0.73) | CYP1A2GAAALDH1A1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2021097427-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097427-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| CN-1137116-C | Dioxane derivatives, liquid-crystal compositions containing same and liquid-crystal display devices made by using same | — | 2004-02-04 | — | — | CN | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
| CN-1211978-A | Dioxane derivatives, liquid-crystal compositions containing same and liquid-crystal display devices made by using same | CHISSO CORP (JP) | 1999-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | CHRM1, RXFP3, NPY5R | CYP1A2 447/4885GAA 2757/4885ALDH1A1 3587/4885 |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | CHRM1, RXFP3, NPY5R | CYP1A2 447/4885GAA 2757/4885ALDH1A1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.